Adagio Medical Holdings, Inc.

Adagio Medical Holdings, Inc. (ADGM) reported a net loss of $25.1 million for the fiscal year ended December 31, 2025, with no revenue generated during the period. This follows a strategic realignment in February 2025 that paused the limited European launch of its vCLAS catheter and significantly reduced commercial activities. The company incurred significant operating expenses, including $10.6 million in research and development and $10.6 million in selling, general, and administrative costs. As of December 31, 2025, the company had cash and cash equivalents of $17.1 million and an accumulated deficit of $95.6 million. Management has raised substantial doubt about the company's ability to continue as a going concern, noting that existing cash is insufficient to fund operations for the next twelve months, with resources expected to last only into the third quarter of 2026 based on current plans.

Key Takeaways